Osteoporosis leads to severe disability and mortality in men. The use of anti-osteoporosis treatment can effectively raise bone mineral density and minimize the risk of vertebral compression fractures in males with osteoporosis.

To determine the usefulness of pharmacological therapy in men suffering from osteoporosis and provide evidence-based management approaches.

Twenty clinical studies were included in this meta-analysis after searching renowned medical literature databases like Embase, PubMed, and Web of Science. The relative risk and pooled standardized mean difference (SMD) were evaluated. Detection of heterogeneity between included studies and publication bias was done.

The pooled SMD for mean percentage changes from baseline in lumbar spine bone mineral density (BMD) between the two groups was found to be 4.95. The overall SMD for mean percentage change in femoral neck BMD and total hip BMD is shown below:

The total relative risk for the occurrence of vertebral fractures was 0.50. The pooled RR for non-vertebral fractures and clinical fractures were 0.74 and 0.81 respectively.

The use of pharmacological therapy increases lumbar spine BMD, femoral neck BMD, hip BMD, and reduces the occurrence of vertebral fractures in males with osteoporosis.